Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...

Vertex Pharmaceuticals (NASDAQ ... But far from being a reason to doubt the long-term potential of this stock, this setback is an opportunity to buy the dip for those who are willing to hold ...

Vertex Pharmaceuticals reported disappointing Q1 ... I think the biotech stock remains an excellent long-term pick because of the growth prospects for Alyftrek and Journavx as well as the ...

In recent trading, shares of Vertex Pharmaceuticals, Inc. (Symbol: VRTX) have crossed above the average analyst 12-month target price of $383.87, changing hands for $385.76/share. When a stock ...

Shares of Vertex Pharmaceuticals Inc. VRTX slipped 1.60% to $484.82 Monday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 0. ...

VERTEX PHARMACEUTICALS insiders have traded $VRTX stock on the open market 21 times in the past 6 months. Of those trades, 0 have been purchases and 21 have been ...

Vertex Pharmaceuticals' Q2 financials showed strong ... Taking into account the pipeline drug opportunities, VRTX's stock looks undervalued. VRTX's quarterly revenue totaled $2.49 billion ...

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Vertex Pharmaceuticals wasn’t one of them. The 10 stocks that ...